ranQ
ranQ
ranQ
DirectoryIndustriesPlacesKnowledgeComparisonsSoon
Sign inCheck visibility
ranQHSG Startup LabelRecognised by the
HSG Startup Label

The leading AI company directory, built to boost AI visibility.

DEENFRIT
Product
  • Pricing
  • Directory
  • Industries
  • Trust Score
Company
  • About
  • Partner program
  • Contact
  • Legal
© 2026 cohaga AG · All Rights Reserved · St. Gallen, Switzerland · Imprint746,904 companies indexed · Last updated: today
DirectoryBusiness & Technical ServicesResearch instituteBaselVaderis Therapeutics AG
Vaderis Therapeutics AG Logo
Verified· 3 sourcesTrust Score
Summary

About the company

The core activity of Vaderis Therapeutics AG is the development of medications, particularly in the areas of rare diseases, nephrology, vascular diseases, fibrosis, anti-infectives, and immunology. The company focuses on the early clinical development of new molecules and has experience in collaborating with companies such as Novartis.

AI-generated
Offering

Products & services

Industry:Research institutePharmaceutical company
LeadhubOutbound Leads by COHAGA

Looking for direct email addresses and phone numbers?

Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.

Discover Leadhub
4.1/5

Vaderis Therapeutics AG

✓ Offered4
Development of therapies for HHT
Development of targeted therapies for Hereditary Hemorrhagic Telangiectasia (HHT) and other rare vascular diseases, from scientific target definition to clinical development.
Clinical development of Engasertib
Clinical development of Engasertib as a selective AKT1/2 inhibitor for the treatment of HHT, focusing on the pipeline and clinical trials.
Research into rare vascular diseases
Research into HHT pathophysiology, vascular signalling pathways and genetic causes to develop targeted interventions against abnormal blood vessel formation.
Clinical trials
Conducting and using clinical trials as a preferred access route to investigational medicinal products for patients with HHT.
Trust & reputation

ranQ Trust Score of Vaderis Therapeutics AG: 4.1 out of 5.0

Trust Score4.1/ 5.0

High

x

Data basis 58% · As of November 2026

Without public customer reviews the score stays capped.

Vaderis Therapeutics AG has no value in the Reputation area of the ranQ Trust Score because no data is available. The area carries 42% of the weighting and drops out of the calculation for this profile; it does not lower the score, only the reported data basis.
x
CriterionValueWeight
  • Review quality: No data point — the criterion is taken out of the weighting and does not lower the score.—24%
  • Review volume: No data point — the criterion is taken out of the weighting and does not lower the score.—10%
  • Review recency: No data point — the criterion is taken out of the weighting and does not lower the score.—8%
Vaderis Therapeutics AG scores 79.5 out of 100 points in the Substance area of the ranQ Trust Score. This area carries 28% of the weighting.
x
CriterionValueWeight
  • Establishment: Years since founding or brand launch, logarithmic. The maximum is reached at 15 years.70.212%
  • Company size: The headcount band, researched by ranQ or stated by the company. It is scored in steps rather than by head count, because the data only provides bands.82.07%
Vaderis Therapeutics AG scores 85.0 out of 100 points in the Identity area of the ranQ Trust Score. This area carries 22% of the weighting.
x
CriterionValueWeight
  • Verification: Official register entry (commercial register with UID or professional-body record, 55 points), confirmed domain (20 points) and confirmed ranQ profile (up to 25 points, depending on completeness).85.022%
Vaderis Therapeutics AG scores 27.9 out of 100 points in the Visibility area of the ranQ Trust Score. This area carries 8% of the weighting.
x
CriterionValueWeight
  • Website authority: Ahrefs' Domain Rating measures, on a scale of 0 to 100, how strongly a website is linked from other websites. For Swiss SMEs the range up to 40 is typical; the maximum is reached at 35.45.74%
  • Media authority: Quality and number of editorial mentions, weighted by the importance of the source, plus the recency of the latest high-quality mention.10.04%
Qualifications+0.00

Vaderis Therapeutics AG reaches a ranQ Trust Score of 4.1 out of 5.0 — rated «High». No public customer reviews are available for this provider; the rating is based on the remaining criteria. The data basis is 58%, so the score is backed by part of the criteria. As of November 2026.

The Trust Score cannot be bought and is calculated from publicly verifiable data.

Press

Media

August 22, 2022Media
From stealth mode into clinical trials
startupticker.ch

Knowledge

No knowledge articles yet

Once Vaderis Therapeutics AG has claimed this profile, we'll publish editorial articles and case studies here together.

Get started
Comparisons

Vaderis Therapeutics AG in comparison

Soon

Industry comparisons are coming soon

We're preparing industry comparisons that rank Vaderis Therapeutics AG by reviews, experience and specialisations.

Is this your company?

Claim the company profile of Vaderis Therapeutics AG to make its contact details visible. With a plan we additionally create and publish industry comparisons, articles and much more.

Secure profile

Location

Lichtstrasse 35
4056 Basel
Opening hours
Mon
08:00 - 20:00
Tue
08:00 - 20:00
Wed
08:00 - 20:00
Thu
08:00 - 20:00
Fri
08:00 - 20:00
Sat
Closed
Sun
Closed

At a glance

Legal form
Corporation
UID
CHE-464.916.458
Founded
2020 · 6 years
Last commercial register change
September 14, 2026
Employees
21 to 50
Legal form: Graded by liability and disclosure. The weight is kept small: a sole proprietorship is not a dubious company, it is just liable differently.
100.0
6%
  • Branch offices: Branch offices linked in the commercial register. Having none is normal and costs no points.70.03%
    • Full methodology

    Similar companies

    SB
    SOTIO Biotech AG
    Basel
    IF
    Institut für molekulare und klinische Ophthalmologie Basel
    Basel
    RS
    Regeneron Switzerland GmbH
    Basel
    US
    Urovant Sciences GmbH
    Basel
    SC
    St. Clara Forschung AG
    Basel
    IS
    Immunovant Sciences GmbH
    Basel
    IM
    Inari Medical Europe GmbH
    Basel
    PA
    Prosalix AG
    Basel